FDA approves Spark Therapeutics’ retinal disease gene therapy Luxturna, a month ahead of schedule

Interface of retinal pigment epithelium and photoreceptor cells. Source: NIH Open-i   As we discussed in our December 17, 2015 article on this blog, Spark Therapeutics’ (Philadelphia, PA) SPK-RPE65 had achieved positive Phase 3 results at that time. It was expected to reach the U.S. market in 2017. As announced by Spark in [...]

The post FDA approves Spark Therapeutics’ retinal disease gene therapy Luxturna, a month ahead of schedule appeared first on Haberman Associates.